VEGFR2/KDR/Flk1 Cancer Research Results

VEGFR2/KDR/Flk1, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2; human gene symbol KDR; also called Flk-1 or CD309) is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2/PTGS2↓, *IL6↓, *TNF-α↓, *MPO↓, *Synergy↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2/KDR/Flk1↓, p‑FAK↓,
958- Api,    Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma
- in-vitro, Lung, NCIH1299
Hif1a↓, VEGF↓, VEGFR2/KDR/Flk1↓, PDGF↓, angioG↓,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2/KDR/Flk1↓, JNK↑, Beclin-1/ATG6↑, GRP78/BiP↑, eff↑, Synergy↑, Synergy↑, Synergy↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2/PTGS2↓, MMP9↓,
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
angioG↓, TumCG↓, VEGF↓, VEGFR2/KDR/Flk1↓, *toxicity↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, Var, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, VEGFR2/KDR/Flk1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27/CDKN1B↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1 / PDPK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2/KDR/Flk1↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, Var, NA
TumCCA↑, TP53↑, COX2/PTGS2↓, Bax:Bcl2↑, ROS↑, VEGFR2/KDR/Flk1↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27/CDKN1B↑, E-cadherin↓, Fibronectin↓, cMyc↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1/CCL2↓, COX2/PTGS2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, Synergy↑, EGFR↓, Glycolysis↓, Dose?, p27/CDKN1B↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2/KDR/Flk1↓, ChemoSen↑, Synergy↑, Synergy↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
6503- BCP,    The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer
- Review, Var, NA
ChemoSen↑, angioG↓, TumCI↓, TumMeta↓, ROS↑, *ROS↓, chemoP↑, CB2 / CNR2↑, Inflam↓, AntiTum↑, *BioAv↑, *BBB↑, Apoptosis↑, TumCP↑, TumCCA↑, RadioS↑, DNArepair↓, ROS↑, STAT3↓, *BioEnh↑, Pain↓, AntiBio↓, ROS↑, Dose↝, NF-kB↓, MAPK↓, TNF-α↓, IL1β↓, IL6↓, cl‑PARP↑, Casp↑, BAX↑, Bcl-2↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP2↓, p‑p38↓, p‑ERK↓, EPR↑, P-gp/ABCB1↓, MRP1/ABCC1↓, *NRF2↑, *antiOx↑,
5728- BF,    Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, TumCCA↑, Bcl-2↝, BAX↝, Cyt‑c↝, Casp3↝, PARP↝, P21↝, cycD1/CCND1↝, COX2/PTGS2↝, p‑VEGFR2/KDR/Flk1↓, EGFR↓, Akt↓, NF-kB↓, p44↓,
9204- BITC,    Benzyl isothiocyanate-mediated growth inhibition of MDA-MB-231 human breast cancer xenograft is associated with reduced cell proliferation, inhibition of angiogenesis, and induction of autophagy
- vitro+vivo, BC, MDA-MB-231
TumCG↓, Weight∅, Ki-67↓, PCNA↓, angioG↓, VEGFR2/KDR/Flk1↓,
2775- Bos,    The journey of boswellic acids from synthesis to pharmacological activities
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
ROS↑, ER Stress↑, TumCG↓, Apoptosis↑, Inflam↓, ChemoSen↑, Casp↑, ERK↓, cl‑PARP↑, AR↓, cycD1/CCND1↓, VEGFR2/KDR/Flk1↓, CXCR4↓, radioP↑, NF-kB↓, VEGF↓, P21↑, Wnt↓, β-catenin/ZEB1↓, Cyt‑c↑, MMP2↓, MMP1↓, MMP9↓, PI3K↓, MAPK↓, JNK↑, *5LO↓, *NRF2↑, *HO-1↑, *MDA↓, *SOD↑, *hepatoP↑, *ALAT↓, *AST↓, *LDH↑, *CRP↓, *COX2/PTGS2↓, *GSH↑, *ROS↓, *Imm↑, *Dose↝, *eff↑, *neuroP↑, *cognitive↑, *IL6↓, *TNF-α↓, *AntiArt↑, *AntiDiabetic↑, *antiAll↑,
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
*ROS↓, *IronCh↑, *AntiAge↑, *antiOx↑, *Inflam↓, *neuroP↑, *lipid-P↓, *toxicity↓, *NOX4↓, *SOD↑, *HNE↓, *IL6↓, *TNF-α↓, *IL1β↓, *Sepsis↓, *Stroke↓, *GABA↝, *Aβ↓, Glycolysis↓, AntiTum↑, p‑Akt↓, TumCCA↑, angioG↓, VEGFR2/KDR/Flk1↓, NF-kB↓,
6143- Cin,    Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling
- in-vitro, Var, NA
VEGFR2/KDR/Flk1↓, angioG↓,
6195- Cuc,    Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends
- Review, Var, NA
TumCG↓, Apoptosis↑, TumCCA↑, TumMeta↓, angioG↓, chemoPv↑, BioAv↓, Half-Life↝, cycD1/CCND1↓, cycE/CCNE↓, Casp3↑, cl‑PARP↑, JNK↑, Akt↓, ERK↓, survivin↓, XIAP↓, Bcl-2↓, Mcl-1↓, ROS↑, NRF2↓, FAK↓, MMP9↓, VEGF↓, VEGFR2/KDR/Flk1↓, *NF-kB↓, TLR4↝, NLRP3↑, Pyro↑, GSH↓,
6185- Cuc,    Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- Review, Var, NA - Review, Arthritis, NA - Review, AD, NA
*Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *AntiCan↑, *toxicity↝, *BioAv↓, *HO-1↑, *NRF2↑, *NLRP3↑, *SOD↑, *SOD1↑, *ROS↓, *AntiAge↑, *ARE↑, *STAT↓, *NF-kB↓, *neuroG↑, *memory↑, ROS↑, NLRP3↑, CIP2A↓, Akt↓, STAT3↑, VEGFR2/KDR/Flk1↓, DNMTs↓, MAPK↓, YAP/TEAD↓, PI3K↓, Wnt↓, NOTCH↓, TumCCA↑, TumCG↓, TumCP↓, FAK↑, MMP9↓, TumAuto↑, toxicity↝, BioAv↓, Half-Life↝, BioAv↑, selectivity∅,
8855- DIM,    A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78)
- vitro+vivo, Pca, PC3 - in-vitro, PC, MIA PaCa-2 - in-vitro, CRC, COLO205 - in-vitro, Nor, HUVECs
angioG↓, GRP78/BiP↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2/KDR/Flk1↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP/DDIT3↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1618- EA,    A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action
- Review, BC, NA
TumCCA↑, TumCMig↓, TumCI↓, TumMeta↓, Apoptosis↑, TGF-β↓, SMAD3↓, CDK6↓, PI3K↓, Akt↓, angioG↓, VEGFR2/KDR/Flk1↓, MAPK↓, NEDD9↓, NF-kB↓, eff↑, eff↑, RadioS↑, ChemoSen↑, DNAdam↑, eff↑, *toxicity∅, *toxicity∅,
27- EA,    Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
- in-vivo, PC, PANC1
HH↓, Gli1↓, GLI2↓, CDK1/2/5/9↓, p‑Akt↓, NOTCH1↓, Shh↓, Snail↓, E-cadherin↑, NOTCH3↓, HEY1↓, TumCG↓, TumCP↓, Casp3↑, cl‑PARP↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, CDK6↓, BAX↑, COX2/PTGS2↓, Hif1a↓, VEGF↓, VEGFR2/KDR/Flk1↓, IL6↓, IL8↓, MMP2↓, MMP9↓, NA↓,
643- EGCG,    New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate
- Analysis, Var, NA
H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2/KDR/Flk1↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,
684- EGCG,    Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation
- in-vitro, CRC, NA
eff↑, Akt↓, VEGFR2/KDR/Flk1↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1/ATG6↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2/KDR/Flk1↓, IAP2/BIRC3↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
6986- Form,    Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway
- in-vitro, Var, NA
other↝, AntiCan↑, VEGF↓, Apoptosis↑, Bax:Bcl2↑, cl‑Casp3↑, cl‑Casp9↑, Cyt‑c↑, Hif1a↓, MEK↓, ERK↓, VEGFR2/KDR/Flk1↓, angioG↓,
8589- FS,    Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets
- Study, Var, NA
Risk↓, Ingr?, *antiOx?, *Inflam↓, *Estro↓, *Ingr↑, *neuroP↑, *Obesity↓, TumMeta↓, TumCP↓, *AntiAg↑, *AntiDiabetic↑, *ROS↓, *GutMicro↑, FOXM1↓, PCNA↓, Ki-67↓, CDK2↓, Akt↓, PDGF↓, ERK↓, p‑GSK‐3β↓, IGFR↓, p‑MDM2↓, EGFR↓, FASN↓, CYP3A4↓, COX2/PTGS2↓, Cyt‑c↑, cl‑PARP↑, Casp3↑, p‑P53↑, Bcl-2↓, VEGF↓, VEGFR2/KDR/Flk1↓, BRCA1↓, BRCA2↓, survivin↓, GADD45A↓, FAK↓, pax↓, Rho↓, Rac1↓, Cdc42↓, MMP2↓, TIMP1↑, TIMP2↑, angioG↓, MMP↓, ChemoSen↑,
7047- GA,    Gallic acid-conjugated 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone induces apoptosis and downregulates PI3K/Akt signaling through VEGFR-2 targeting in non-small cell lung cancer (NSCLC)
- in-vitro, NSCLC, A549
TumCP↓, selectivity↑, AKT1↓, EP4/PTGER4↓, PDK1 / PDPK1↓, VEGFR2/KDR/Flk1↓,
1241- GSE,  PACs,    Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling
- in-vitro, Nor, NA
*VEGF↓, *MMP2↓, *MMP9↓, *p‑VEGFR2/KDR/Flk1↓,
7365- HibSad,    Insight into the molecular evidence supporting the remarkable chemotherapeutic potential of Hibiscus sabdariffa L
- Review, Var, NA
chemoPv↑, selectivity↑, TumCCA↑, Apoptosis↑, TumAuto↑, TumMeta↓, ATG5↑, Beclin-1/ATG6↑, LC3II↑, MMP2↓, MMP9↓, CD31/PECAM-1↓, VEGF↓, uPA↓, TIMP2↑, NF-kB↓, p38↑, P53↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, BAX↑, Cyt‑c↑, TNF-α↑, Fas↑, FasL↑, JNK↑, cJun↑, angioG↓, VEGFR2/KDR/Flk1↓, PCNA↓, CCN2/CTGF↓, RAGE↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2/KDR/Flk1↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2/PTGS2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP/DDIT3↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp/ABCB1↓, Half-Life↓, Half-Life↝, Synergy↑, BioAv↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2/KDR/Flk1↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
7756- ISL,    Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway
- vitro+vivo, BC, MCF7 - vitro+vivo, BC, MDA-MB-231
AntiCan↑, VEGF↓, TumCI↓, TumCMig↓, Hif1a↓, TumCG↓, angioG↓, VEGFR2/KDR/Flk1↓, Apoptosis↑, toxicity↓, TumCCA↑, Inflam↓, ROS↑,
8000- itraC,    The anti-cancer effects of itraconazole in epithelial ovarian cancer
- in-vivo, Ovarian, NA
ChemoSen↑, HH↓, mTOR↓, angioG↓, VEGFR2/KDR/Flk1↓,
7984- itraC,    The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells
- in-vitro, Nor, NA
VEGFR2/KDR/Flk1↓, angioG↓, toxicity↓, mTOR↓,
7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, DCR↑, PFS↑, CA125↓, P-gp/ABCB1↓, VEGFR2/KDR/Flk1↑, toxicity↓, QoL↑, toxicity↝,
8075- KAE,  QC,    Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies
- Review, Var, NA
tumCV↓, Apoptosis↑, TumCP↓, TumCMig↓, PI3K↓, Akt↓, MAPK↓, NF-kB↓, P53↑, Bcl-2↓, PARP↑, ERK↓, IQGAP3↓, γH2AX↑, cl‑Casp3↑, cl‑Casp9↑, Rho↓, Rac1↓, MMP2↓, MMP9↓, CTSB↓, CTSD↓, O-Glc↓, SERPINH1/HSP47↓, EMT↓, angioG↓, EGF↓, VEGFR2/KDR/Flk1↓, RadioS↑,
8229- LCA,    Licochalcone A: a review of its pharmacology activities and molecular mechanisms
- Review, Nor, NA
*Inflam↓, *NO↓, *NF-kB↓, *TAC↑, Apoptosis?, TumCCA↑, TumCI↓, TumMeta↓, TumCP↓, MAPK↓, Akt↓, IL6↓, IL8↓, VEGFR2/KDR/Flk1↓, LC3II↑, PI3K↓, mTOR↓, mtDam↑, MMP↓, *NRF2↑, *PGE2↓, *Obesity↓, *SIRT1↑, *AMPK↑, *AntiFungal↑, *AntiP↑, *BMD↑, *GastroP↑,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27/CDKN1B↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2/PTGS2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24/HTB-9
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31/PECAM-1↓, CA↓,
8654- MBZ,  SUL,    Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model
- in-vivo, Colon, HT-29 - in-vitro, Colon, SW48
Synergy↑, COX2/PTGS2↓, angioG↓, VEGFR2/KDR/Flk1↓, Ki-67↓, chemoPv↑,
8648- MBZ,    Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
- Review, Var, NA
angioG↓, MMPs↓, MDR1↓, TubPol↓, RadioS?, ChemoSen?, TumCG↓, TumMeta?, OS↑, BioAv↓, BioAv↑, BBB↑, mitA↑, HH↓, Shh↓, Synergy↑, Gli1↓, PTCH2↓, XIAP↓, cl‑PARP↑, Casp3↑, BRAF↓, MEK↓, SYN1↑, Cyt‑c↑, TumVol↓, VEGFR2/KDR/Flk1↓, VEGF↓, VCAM-1↓, DYRK1B↓, QoL↑, Dose↝,
3464- MF,    Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology
- Review, Var, NA
AntiTum↑, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↑, Diff↑, angioG↓, TumMeta↓, EPR↑, ChemoSen↑, ROS↑, DNAdam↑, P53↑, Akt↓, MAPK↑, Casp9↑, VEGFR2/KDR/Flk1↓, P-gp/ABCB1↓,
3482- MF,    Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice
- in-vitro, Nor, NA
*cardioP↑, *VEGF↑, *VEGFR2/KDR/Flk1↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,
524- MF,    Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs)
- vitro+vivo, PC, MS-1 - vitro+vivo, PC, HUVECs
other↓, TumCP↓, TumCMig↓, VEGFR2/KDR/Flk1↓, TumVol↓, HSP70/HSPA5↓, HSP90↓, TumCCA↑, angioG↓,
8765- MSM,    Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway
- vitro+vivo, Bladder, NA
*toxicity↓, tumCV↓, TumCMig↓, TumCG↓, STAT3↓, STAT5↓, IGF-1R↓, VEGF↓, VEGFR2/KDR/Flk1↓, TumMeta↓, Synergy↑,
5164- PLB,    Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2
- vitro+vivo, CRC, NA - in-vitro, Pca, NA
TumCP↓, TumCMig↓, angioG↓, VEGFR2/KDR/Flk1↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2/KDR/Flk1↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2/PTGS2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, Synergy↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, Synergy↑, Synergy↑, Synergy↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP/DDIT3↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2/KDR/Flk1↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1/ATG6↑, IL1β↓, CRP↓, IL10↓, COX2/PTGS2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2/KDR/Flk1↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP/DDIT3↑,
92- QC,    Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways
- vitro+vivo, Pca, HUVECs - vitro+vivo, Pca, PC3
VEGFR2/KDR/Flk1↓, HemoG↓, Akt↓, mTOR↓, P70S6K↓, angioG↓,

Showing Research Papers: 1 to 50 of 62
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 62

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx⇅, 1,   Fenton↑, 1,   GSH↓, 2,   GSH↑, 2,   GSTs↑, 1,   H2O2↓, 1,   H2O2↑, 1,   HO-1↓, 2,   lipid-P↓, 1,   MDA↓, 1,   NQO1?, 1,   NRF2↓, 2,   NRF2↑, 4,   p‑NRF2↓, 1,   ROS↓, 2,   ROS↑, 21,   ROS⇅, 2,   i-ROS↑, 1,   mt-ROS↑, 1,   SOD↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 3,   CDC25↓, 3,   EGF↓, 3,   mtDam↑, 2,   OCR↓, 1,   PDH↝, 1,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   AMPK↑, 4,   ATP↓, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 4,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   O-Glc↓, 1,   PCK1↓, 1,   PDK1 / PDPK1↓, 2,   PKM2↓, 1,   SIRT1↓, 2,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 18,   ASK1↑, 1,   Bak↑, 1,   BAX↑, 15,   BAX↝, 1,   Bax:Bcl2↑, 3,   Bcl-2↓, 17,   Bcl-2↝, 1,   Bcl-xL↓, 3,   BID↓, 1,   BIM↓, 1,   Casp↑, 6,   Casp12↑, 1,   Casp3↓, 3,   Casp3↑, 17,   Casp3↝, 1,   cl‑Casp3↑, 4,   Casp6↓, 1,   Casp7↑, 1,   Casp8↓, 1,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9↓, 1,   Casp9↑, 12,   cl‑Casp9↑, 3,   cFLIP↓, 1,   Cyt‑c↑, 14,   Cyt‑c↝, 1,   Diablo↑, 2,   DR5↑, 9,   FADD↑, 1,   Fas↑, 7,   FasL↑, 2,   Ferroptosis↑, 1,   HEY1↓, 1,   IAP2/BIRC3↓, 1,   iNOS↓, 3,   Mcl-1↓, 5,   Mcl-1↑, 1,   MDM2↓, 1,   p‑MDM2↓, 1,   oncosis↑, 1,   p38↑, 5,   p‑p38↓, 2,   Pyro↑, 1,   survivin↓, 11,   TRAIL↑, 1,   TUNEL↑, 1,   XIAP↓, 6,   YAP/TEAD↓, 3,   YAP/TEAD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 26,   Akt↑, 1,   p‑Akt↓, 4,   AKT1↓, 1,   BRAF↓, 1,   CIP2A↓, 2,   cMET↓, 2,   cSrc↓, 1,   DYRK1B↓, 1,   EF-1α↓, 1,   EGFR↓, 10,   ERK↓, 12,   ERK↑, 1,   p‑ERK↓, 2,   FGFR1↓, 1,   HER2/EBBR2↓, 1,   Hippo↓, 1,   IGF-1R↓, 1,   IGFR↓, 2,   IKKα↓, 1,   JAK1↓, 1,   JAK2↓, 3,   JNK↑, 8,   MAPK↓, 13,   MAPK↑, 3,   MEK↓, 4,   mTOR↓, 13,   p‑mTOR↓, 2,   mTORC2↓, 1,   P70S6K↓, 3,   PDGFR-BB↑, 1,   PI3K↓, 20,   PKCδ↓, 3,   PTEN↑, 4,   Raf↓, 3,   c-Raf↓, 1,   RAS↓, 3,   p‑S6K↓, 1,   Sp1/3/4↓, 1,   Src↑, 1,   STAT3↓, 12,   STAT3↑, 1,   p‑STAT3↓, 2,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↑, 2,   cMyc↓, 9,   p‑cMyc↑, 1,   DNMT1↓, 2,   DNMTs↓, 2,   EZH2↓, 1,   FOXM1↓, 1,   FOXO↓, 1,   FOXO↑, 1,   H3↑, 1,   p‑H3↓, 1,   ac‑H3↑, 2,   H4↑, 1,   ac‑H4↑, 1,   HATs↑, 2,   HDAC↓, 5,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   miR-21↓, 1,   miR-21↑, 1,   Myc↓, 1,   n-MYC↓, 1,   OCT4↓, 2,   other↓, 1,   other↝, 1,   SOX2↓, 4,   SOX4↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   cl‑CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 6,   GRP78/BiP↓, 1,   GRP78/BiP↑, 4,   HSP70/HSPA5↓, 3,   HSP90↓, 1,   SERPINH1/HSP47↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 3,   ATG7↑, 2,   Beclin-1/ATG6↑, 5,   CTSB↓, 1,   CTSD↓, 1,   LC3B-II↑, 2,   LC3II↑, 6,   LC3s↑, 1,   TumAuto↑, 8,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   p‑ATM↑, 1,   p‑ATR↑, 1,   BRCA1↓, 1,   BRCA2↓, 1,   DNAdam↑, 5,   DNArepair↓, 1,   HR↓, 1,   hTERT/TERT↓, 1,   p16↑, 2,   P53↓, 1,   P53↑, 14,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 2,   PARP↝, 1,   cl‑PARP↑, 13,   PARP1↑, 1,   PCNA↓, 8,   RAD51↓, 1,   Telomerase↓, 2,   TOP1↓, 1,   TOP2↓, 2,   TP53↑, 1,   UHRF1↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1/2/5/9↓, 1,   CDK2↓, 9,   CDK2↑, 2,   CDK4↓, 5,   CDK4/6↓, 1,   CDK6↓, 6,   CHK1↓, 1,   CHK1↑, 1,   p‑CHK1↑, 1,   Chk2↑, 1,   p‑Chk2↑, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 13,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 3,   cycE1↓, 1,   E2Fs↓, 1,   GADD45A↓, 1,   Ki-67↓, 9,   MAD↓, 1,   mitA↑, 1,   P21?, 1,   P21↑, 8,   P21↝, 1,   p27/CDKN1B↑, 5,   p‑pRB↓, 1,   p‑RB1↓, 1,   TubPol↓, 1,   TumCCA↑, 24,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   ALDH1A1↓, 1,   CD133↓, 2,   CSCs↓, 5,   Diff↓, 2,   Diff↑, 1,   EP4/PTGER4↓, 1,   FGF↓, 1,   Gli1↓, 3,   HH↓, 4,   IGF-1↓, 2,   p‑IGF-1↓, 1,   IGFBP3↑, 1,   Ki-67↓, 9,   mTORC1↓, 2,   p‑mTORC1↓, 1,   Nanog↓, 2,   Nestin↓, 2,   NICD↓, 1,   NOTCH↓, 7,   NOTCH1↓, 4,   NOTCH3↓, 2,   PTCH2↓, 1,   Shh↓, 5,   Smo↓, 1,   STAT1↓, 1,   TAZ↓, 1,   TumCG↓, 13,   TumCP↓, 15,   TumCP↑, 1,   Wnt↓, 7,   Wnt/(β-catenin)↓, 2,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AntiAg↓, 1,   AP-1↓, 2,   AXL↓, 1,   CA↓, 1,   Ca+2↑, 5,   CAFs/TAFs↓, 1,   CCN2/CTGF↓, 1,   Cdc42↓, 1,   DLC1↑, 1,   E-cadherin↓, 2,   E-cadherin↑, 9,   EMT?, 1,   EMT↓, 13,   FAK↓, 4,   FAK↑, 1,   p‑FAK↓, 1,   Fibronectin↓, 1,   GLI2↓, 1,   IQGAP3↓, 1,   ITGA5↓, 1,   ITGB1↑, 1,   MMP1↓, 2,   MMP13↓, 1,   MMP2↓, 17,   MMP7↓, 2,   MMP9↓, 20,   MMPs↓, 8,   N-cadherin↓, 6,   NCAM↑, 1,   NEDD9↓, 1,   p44↓, 1,   pax↓, 1,   PDGF↓, 5,   Rac1↓, 2,   Rho↓, 3,   Slug↓, 2,   SMAD3↓, 1,   Snail?, 1,   Snail↓, 7,   TGF-β↓, 5,   TGF-β↑, 1,   TIMP1↓, 1,   TIMP1↑, 2,   TIMP2↓, 1,   TIMP2↑, 4,   TSP-1↑, 2,   TumCI↓, 8,   TumCMig↓, 9,   TumMeta?, 1,   TumMeta↓, 14,   Twist↓, 5,   uPA↓, 8,   uPAR↓, 1,   Vim↓, 6,   Zeb1↓, 4,   ZEB2↓, 1,   β-catenin/ZEB1↓, 7,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 32,   CD31/PECAM-1↓, 3,   eNOS↓, 1,   Hif1a↓, 17,   NO↓, 2,   NO↑, 1,   VCAM-1↓, 1,   VEGF↓, 29,   VEGFR2/KDR/Flk1↓, 57,   VEGFR2/KDR/Flk1↑, 1,   p‑VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   CLDN2↓, 1,   EPR↑, 2,   GLUT1↓, 2,   MMP↓, 11,   MPT↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 1,   CCR7↓, 1,   CD44↓, 1,   COX2/PTGS2↓, 12,   COX2/PTGS2↝, 1,   CXCL1↓, 1,   CXCL12↓, 1,   CXCR4↓, 7,   DR4↑, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↓, 2,   IL10↓, 4,   IL12↓, 1,   IL1β↓, 2,   IL2↑, 2,   IL4↓, 1,   IL6↓, 9,   IL8↓, 3,   IL8↑, 1,   Inflam↓, 5,   M2 MC↓, 1,   MCP1/CCL2↓, 1,   MDSCs↓, 1,   MIP2↓, 1,   NF-kB↓, 19,   p‑NF-kB↑, 1,   NLRP3↑, 2,   p65↓, 2,   PD-1↓, 1,   PGE2↓, 4,   PSA↓, 1,   RAGE↓, 1,   TLR4↓, 1,   TLR4↝, 1,   TNF-α↓, 6,   TNF-α↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

SYN1↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   PPARγ↓, 2,   PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 2,   ChemoSen?, 1,   ChemoSen↓, 1,   ChemoSen↑, 15,   CompStab↝, 1,   CYP1A1↓, 1,   CYP1A2↓, 1,   CYP1B1↑, 1,   CYP3A4↓, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 7,   eff↑, 7,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 3,   MDR1↓, 2,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 4,   P450↓, 1,   RadioS?, 1,   RadioS↑, 6,   selectivity↑, 8,   selectivity∅, 1,   Synergy↑, 18,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   BRAF↓, 1,   BRCA1↓, 1,   CA125↓, 1,   CRP↓, 1,   EGFR↓, 10,   EZH2↓, 1,   FOXM1↓, 1,   HemoG↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 9,   LDH↓, 1,   LDH↑, 1,   Myc↓, 1,   PSA↓, 1,   RAGE↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   AntiTum↑, 4,   cardioP↑, 1,   chemoP↑, 5,   chemoPv↑, 3,   ChemoSideEff↓, 1,   DCR↑, 1,   hepatoP↑, 3,   neuroP↑, 2,   OS↑, 6,   Pain↓, 1,   PFS↑, 1,   QoL↑, 2,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 3,   toxicity↝, 4,   TumVol↓, 2,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,  
Total Targets: 465

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx?, 1,   antiOx↑, 10,   ARE↑, 1,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 2,   HNE↓, 1,   HO-1↑, 2,   Keap1↓, 1,   lipid-P↓, 2,   MDA↓, 3,   MPO↓, 1,   NOX4↓, 1,   NRF2↑, 5,   ROS↓, 11,   SOD↑, 6,   SOD1↑, 1,   TAC↑, 1,   TBARS↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 2,   AMPK↑, 1,   H2S↑, 1,   NAD↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   PI3K↓, 2,   STAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FGF↑, 1,   neuroG↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   ITGB1↑, 1,   MMP2↓, 1,   MMP9↓, 1,   SLIT2↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   CD31/PECAM-1↓, 1,   Hif1a↑, 1,   NO↓, 3,   VEGF↓, 2,   VEGF↑, 1,   VEGFR2/KDR/Flk1↓, 1,   VEGFR2/KDR/Flk1↑, 1,   p‑VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   IL1β↓, 2,   IL4↓, 1,   IL5↓, 1,   IL6↓, 4,   Imm↑, 1,   Inflam↓, 12,   NF-kB↓, 4,   NLRP3↑, 1,   PGE2↓, 2,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

GABA↝, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Estro↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 2,   BioEnh↑, 1,   Dose↝, 1,   eff↑, 1,   GSTA1↑, 1,   Half-Life↝, 1,   Synergy↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   BMD↑, 1,   BP↓, 1,   creat↓, 1,   CRP↓, 2,   IL6↓, 4,   LDH↓, 2,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2,   antiAll↑, 2,   AntiArt↑, 1,   AntiCan↑, 2,   AntiDiabetic↑, 2,   cardioP↑, 2,   cognitive↑, 2,   hepatoP↑, 3,   memory↑, 2,   neuroP↑, 7,   Obesity↓, 2,   Stroke↓, 1,   toxicity↓, 4,   toxicity↝, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiP↑, 1,   GutMicro↑, 2,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↑, 1,  
Total Targets: 103

Scientific Paper Hit Count for: VEGFR2/KDR/Flk1, Vascular Endothelial Growth Factor Receptor 2
5 Quercetin
4 Ramucirumab (CYRAMZA)
3 Artemisinin
3 Ellagic acid
3 itraconazole
3 Magnetic Fields
3 Thymoquinone
2 Berberine
2 Cucurbitacin
2 EGCG (Epigallocatechin Gallate)
2 Luteolin
2 mebendazole
2 Sulforaphane (mainly Broccoli)
1 Allicin (mainly Garlic)
1 Apigenin (mainly Parsley)
1 Baicalein
1 Beta-Caryophyllene
1 Bufalin/Huachansu
1 Benzyl isothiocyanate
1 Boswellia (frankincense)
1 Carnosine
1 Cinnamon
1 Diindolylmethane
1 Fisetin
1 Formononetin
1 Flaxseed/Linseed
1 Gallic acid
1 Grapeseed extract
1 Proanthocyanidins
1 Hibiscus sabdariffa
1 Honokiol
1 HydroxyTyrosol
1 Isoliquiritigenin
1 Kaempferol
1 Licochalcone A
1 Magnolol
1 Sulindac
1 Methylsulfonylmethane
1 Plumbagin
1 α-Santalol/Sandalwood oil
1 Gemcitabine (Gemzar)
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:768  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page